NIH Exploratory/Developmental Grants Phase II (R33)
Funds Exploratory/Developmental Grants Phase II awards, NIH's R33 mechanism.
The Exploratory/Developmental Grants Phase II (R33) is the R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from …
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.
Funds an investigator's own phase I trial in heart, lung, blood or sleep disease — with every regulatory approval already in hand at award.
Funds three years replicating target engagement for a psychosocial intervention and testing whether that engagement tracks clinical change.
Funds early-stage testing of a novel-mechanism drug or a device for mental disorders, designed to show a dose-dependent effect on the target.
Funds mechanistic work on the host biology that decides who responds to a probiotic and who does not.
Funds three years replicating a natural product's effect on its target in people, for teams that have already done the pharmacokinetics work.
Funds the development and hard technical validation that turns a working cancer research technology into one other laboratories will actually adopt.
Funds further development and rigorous technical validation of a cancer research technology that has already cleared basic feasibility.
Funds rigorously validating a transformative, multi-use platform or technology aimed at heart, lung, blood or sleep disease.
Funds turning a preliminary drug, biologic or combination-product lead into a combination-product prototype for heart, lung, blood or sleep disease.
Funds refining a medical-device prototype's design, assays and research tools for heart, lung, blood or sleep disease.